ClinicalTrials.gg
CompletedNCT03067441Updated Mar 1, 2021Results posted

Assessment of the Long-Term Safety and Efficacy of Bempedoic Acid (CLEAR Harmony OLE)

A Phase 3 interventional study of bempedoic acid in Hypercholesterolemia and Atherosclerotic Cardiovascular Disease, sponsored by Esperion Therapeutics, Inc.. Completed at 3 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-03-01.

Sponsored by Esperion Therapeutics, Inc. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,462
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 21 studies testing bempedoic acid in Hypercholesterolemia — 1 open to participants now, 1 under way, 1 of them phase 3. bempedoic acid · Hypercholesterolemia.

Enrollment
2nd of 21
1,462 · median 126
Started
2017
with 3 others
Phase 3
7 of 21
1 open now
Registered
12th of 21
by date
Lead sponsor
15 of 21
Esperion Therapeutics, Inc.

Among the 21 studies testing bempedoic acid in Hypercholesterolemia, this one is the 2nd largest by enrollment, is one of 4 that started in 2017, is one of 7 in phase 3, and was the 12th registered.

Hypercholesterolemia

1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.

Browse Hypercholesterolemia studies →

Open to participants now

1 of the 21 studies testing bempedoic acid in Hypercholesterolemia is open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

About bempedoic acid

bempedoic acid: first FDA approval 2020 (NEXLETOL), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 55 Hypercholesterolemia studies recruiting now, 23 (42%) set no upper age limit and 20 (36%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies testing bempedoic acid in Hypercholesterolemia, or all of them as a file.
02

Study summary

The purpose of this study is to see if bempedoic acid (ETC-1002) is safe and well-tolerated in patients with high cardiovascular risk and elevated LDL cholesterol that is not adequately controlled by their current therapy.

03

Conditions studied

  • Hypercholesterolemia
  • Atherosclerotic Cardiovascular Disease

Keywords

  • hyperlipidemia
  • cholesterol
  • heterozygous familial hypercholesterolemia
  • atherosclerotic cardiovascular disease
  • ASCVD
  • HeFH
  • LDL
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Successfully completed CLEAR Harmony (1002-040) parent study

Exclusion criteria

Exclusion Criteria:

  • Experienced a treatment-related SAE that led to study drug discontinuation in the CLEAR Harmony (1002-040) parent study.
  • Medical condition requires lipid measurement and/or adjustment of background lipid-regulating therapy.
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
1,462 participants (actual)

Study arms

  • Experimental
    Open-Label bempedoic acid

    bempedoic acid 180 mg tablet

    Drug: bempedoic acid

Interventions

  • bempedoic acid 180 mg tablets taken orally, once per day.

    Also known as: ETC-1002

06

What researchers measure

Primary outcomes

  1. Number of Participants With Treatment-Emergent Adverse Events (TEAEs)

    TEAEs are defined as adverse events that began or worsened in severity after the first dose of investigational medicinal product (IMP) until 30 days after the last dose in the Open-Label Extension (OLE) Study.

    Time frame: Up to Week 82

Secondary outcomes

  1. Percent Change From Parent Study Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at Weeks 52 and 78

    Blood samples were drawn after a minimum 10-hour fast at pre-specified intervals. Percent change from Baseline was calculated as: LDL-C value at Week 52/Week 78 minus Parent Study Baseline value divided by Parent Study Baseline value multiplied by 100. Baseline was defined as the mean of the values at screening and predose Day 1/Week 0 (Visit T1) in the Parent Study.

    Time frame: Baseline; Week 52 and Week 78

  2. Mean Change From Parent Study Baseline in LDL-C at Weeks 52 and 78

    Blood samples were drawn after a minimum 10-hour fast at pre-specified intervals. Mean change from Baseline was calculated as: Mean LDL-C value at Week 52/Week 78 minus Mean Parent Study Baseline value. Baseline was defined as the mean of the values at screening and predose Day 1/Week 0 (Visit T1) in the Parent Study.

    Time frame: Baseline; Week 52 and Week 78

  3. Percent Change From Parent Study Baseline in Non-High-Density Lipoprotein Cholesterol (Non-HDL-C) at Weeks 52 and 78

    Blood samples were drawn after a minimum 10-hour fast at pre-specified intervals. Percent change from Baseline was calculated as: non-HDL-C value at Week 52/Week 78 minus Parent Study Baseline value divided by Parent Study Baseline value multiplied by 100. Baseline was defined as the mean of the values at screening and predose Day 1/Week 0 (Visit T1) in the Parent Study.

    Time frame: Baseline; Week 52 and Week 72

  4. Percent Change From Parent Study Baseline in Total Cholesterol at Weeks 52 and 78

    Blood samples were drawn after a minimum 10-hour fast at pre-specified intervals. Percent change from Baseline was calculated as: Total cholesterol value at Week 52/Week 78 minus Parent Study Baseline value divided by Parent Study Baseline value multiplied by 100. Baseline was defined as the mean of the values at screening and predose Day 1/Week 0 (Visit T1) in the Parent Study.

    Time frame: Baseline; Week 52 and Week 78

  5. Percent Change From Parent Study Baseline in Apolipoprotein B (ApoB) at Weeks 52 and 78

    Blood samples were drawn after a minimum 10-hour fast at pre-specified intervals. Percent change from Baseline was calculated as: ApoB value at Week 52/Week 78 minus Parent Study Baseline value divided by Parent Study Baseline value multiplied by 100. Baseline was defined as the mean of the values at screening and predose Day 1/Week 0 (Visit T1) in the Parent Study.

    Time frame: Baseline; Week 52 and Week 78

  6. Percent Change From Parent Study Baseline in High-Sensitivity C-Reactive Protein (Hs-CRP) at Weeks 52 and 78

    Blood samples were drawn after a minimum 10-hour fast at pre-specified intervals. Percent change from Baseline was calculated as: hs-CRP value at Week 52/Week 78 minus Parent Study Baseline value divided by Parent Study Baseline value multiplied by 100. Baseline was defined as the mean of the values at screening and predose Day 1/Week 0 (Visit T1) in the Parent Study.

    Time frame: Baseline; Week 52 and Week 78

  7. Percent Change From Parent Study Baseline in Triglycerides at Weeks 52 and 78

    Blood samples were drawn after a minimum 10-hour fast at pre-specified intervals. Percent change from Baseline was calculated as: Triglycerides value at Week 52/Week 78 minus Parent Study Baseline value divided by Parent Study Baseline value multiplied by 100. Baseline was defined as the mean of the values at screening and predose Day 1/Week 0 (Visit T1) in the Parent Study.

    Time frame: Baseline; Week 52 and Week 78

  8. Percent Change From Parent Study Baseline in High-Density Lipoprotein Cholesterol (HDL-C) at Weeks 52 and 78

    Blood samples were drawn after a minimum 10-hour fast at pre-specified intervals. Percent change from Baseline was calculated as: HDL-C value at Week 52/Week 78 minus Parent Study Baseline value divided by Parent Study Baseline value multiplied by 100. Baseline was defined as the mean of the values at screening and predose Day 1/Week 0 (Visit T1) in the Parent Study.

    Time frame: Baseline; Week 52 and Week 78

  9. Percent Change From Open-Label Extension (OLE) Study Baseline in LDL-C at Weeks 52 and 78

    Blood samples were drawn after a minimum 10-hour fast at pre-specified intervals. Percent change from Baseline was calculated as: LDL-C value at Week 52/Week 78 minus OLE Study Baseline value divided by Parent Study Baseline value multiplied by 100. Baseline was defined as the last non-missing record prior to treatment start in the OLE Study.

    Time frame: Baseline; Week 52 and Week 78

  10. Mean Change From OLE Baseline in LDL-C at Weeks 52 and 78

    Blood samples were drawn after a minimum 10-hour fast at pre-specified intervals. Mean change from Baseline was calculated as: Mean LDL-C value at Week 52/Week 78 minus Mean OLE Study Baseline value. Baseline was defined as the last non-missing record prior to treatment start in the OLE Study.

    Time frame: Baseline; Week 52 and Week 72

  11. Percent Change From OLE Baseline in Non-HDL-C at Weeks 52 and 78

    Blood samples were drawn after a minimum 10-hour fast at pre-specified intervals. Percent change from Baseline was calculated as: non-HDL-C value at Week 52/Week 78 minus OLE Study Baseline value divided by OLE Study Baseline value multiplied by 100. Baseline was defined as the last non-missing record prior to treatment start in the OLE Study.

    Time frame: Baseline; Week 52 and Week 78

  12. Percent Change From OLE Baseline in Total Cholesterol at Weeks 52 and 78

    Blood samples were drawn after a minimum 10-hour fast at pre-specified intervals. Percent change from Baseline was calculated as: Total Cholesterol value at Week 52/Week 78 minus OLE Study Baseline value divided by OLE Study Baseline value multiplied by 100. Baseline was defined as the last non-missing record prior to treatment start in the OLE Study.

    Time frame: Baseline; Week 52 and Week 78

  13. Percent Change From OLE Baseline ApoB at Weeks 52 and 78

    Blood samples were drawn after a minimum 10-hour fast at pre-specified intervals. Percent change from Baseline was calculated as: ApoB value at Week 52/Week 78 minus OLE Study Baseline value divided by OLE Study Baseline value multiplied by 100. Baseline was defined as the last non-missing record prior to treatment start in the OLE Study.

    Time frame: Baseline; Week 52 and Week 78

  14. Percent Change From OLE Baseline in Hs-CRP at Weeks 52 and 78

    Blood samples were drawn after a minimum 10-hour fast at pre-specified intervals. Percent change from Baseline was calculated as: hs-CRP value at Week 52/Week 78 minus OLE Study Baseline value divided by OLE Study Baseline value multiplied by 100. Baseline was defined as the last non-missing record prior to treatment start in the OLE Study.

    Time frame: Baseline; Week 52 and Week 78

  15. Percent Change From OLE Baseline in Triglycerides at Weeks 52 and 78

    Blood samples were drawn after a minimum 10-hour fast at pre-specified intervals. Percent change from Baseline was calculated as: Triglycerides value at Week 52/Week 78 minus OLE Study Baseline value divided by OLE Study Baseline value multiplied by 100. Baseline was defined as the last non-missing record prior to treatment start in the OLE Study.

    Time frame: Baseline; Week 52 and Week 78

  16. Percent Change From OLE Baseline in HDL-C at Weeks 52 and 78

    Blood samples were drawn after a minimum 10-hour fast at pre-specified intervals. Percent change from Baseline was calculated as: HDL-C value at Week 52/Week 78 minus OLE Study Baseline value divided by OLE Study Baseline value multiplied by 100. Baseline was defined as the last non-missing record prior to treatment start in the OLE Study.

    Time frame: Baseline; Week 52 and Week 78

07

Results

Posted Dec 22, 2020

Participant flow

Participant flow — Overall Study
MilestonePlacebo; Bempedoic AcidBempedoic Acid; Bempedoic Acid
Started492970
Completed459913
Not completed3357
Withdrew: Withdrawal by subject1634
Withdrew: Lost to follow-up75
Withdrew: Adverse event714
Withdrew: Study terminated by sponsor or investigator10
Withdrew: Physician decision13
Withdrew: Other11

Outcome measures

PrimaryNumber of Participants With Treatment-Emergent Adverse Events (TEAEs)

TEAEs are defined as adverse events that began or worsened in severity after the first dose of investigational medicinal product (IMP) until 30 days after the last dose in the Open-Label Extension (OLE) Study.

Time frame:
Up to Week 82
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Emergent Adverse Events (TEAEs)
ParticipantsPlacebo; Bempedoic AcidBempedoic Acid; Bempedoic AcidOLE Bempedoic Acid
Participants with TEAEs3857581143
Participants with serious TEAEs97202299
Participants with TEAEs of mild severity93195288
Participants with TEAEs of moderate severity211403614
Participants with TEAEs of severe severity81160241
SecondaryPercent Change From Parent Study Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at Weeks 52 and 78

Blood samples were drawn after a minimum 10-hour fast at pre-specified intervals. Percent change from Baseline was calculated as: LDL-C value at Week 52/Week 78 minus Parent Study Baseline value divided by Parent Study Baseline value multiplied by 100. Baseline was defined as the mean of the values at screening and predose Day 1/Week 0 (Visit T1) in the Parent Study.

Time frame:
Baseline; Week 52 and Week 78
Reported as:
Mean · percent change
Percent Change From Parent Study Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at Weeks 52 and 78
percent changePlacebo; Bempedoic AcidBempedoic Acid; Bempedoic AcidOLE Bempedoic Acid
Week 52-12.82 ± 23.419-13.80 ± 25.018-13.47 ± 24.485
Week 78-14.99 ± 23.660-14.15 ± 25.113-14.43 ± 24.632
SecondaryMean Change From Parent Study Baseline in LDL-C at Weeks 52 and 78

Blood samples were drawn after a minimum 10-hour fast at pre-specified intervals. Mean change from Baseline was calculated as: Mean LDL-C value at Week 52/Week 78 minus Mean Parent Study Baseline value. Baseline was defined as the mean of the values at screening and predose Day 1/Week 0 (Visit T1) in the Parent Study.

Time frame:
Baseline; Week 52 and Week 78
Reported as:
Mean · milligrams per deciliter (mg/dL)
Mean Change From Parent Study Baseline in LDL-C at Weeks 52 and 78
milligrams per deciliter (mg/dL)Placebo; Bempedoic AcidBempedoic Acid; Bempedoic AcidOLE Bempedoic Acid
Week 52-14.08 ± 24.995-15.77 ± 28.123-15.19 ± 27.109
Week 78-16.11 ± 25.628-16.04 ± 28.929-16.06 ± 27.862
SecondaryPercent Change From Parent Study Baseline in Non-High-Density Lipoprotein Cholesterol (Non-HDL-C) at Weeks 52 and 78

Blood samples were drawn after a minimum 10-hour fast at pre-specified intervals. Percent change from Baseline was calculated as: non-HDL-C value at Week 52/Week 78 minus Parent Study Baseline value divided by Parent Study Baseline value multiplied by 100. Baseline was defined as the mean of the values at screening and predose Day 1/Week 0 (Visit T1) in the Parent Study.

Time frame:
Baseline; Week 52 and Week 72
Reported as:
Mean · percent change
Percent Change From Parent Study Baseline in Non-High-Density Lipoprotein Cholesterol (Non-HDL-C) at Weeks 52 and 78
percent changePlacebo; Bempedoic AcidBempedoic Acid; Bempedoic AcidOLE Bempedoic Acid
Week 52-10.60 ± 20.722-10.55 ± 22.682-10.57 ± 22.033
Week 78-12.50 ± 22.081-10.82 ± 23.910-11.38 ± 23.321
SecondaryPercent Change From Parent Study Baseline in Total Cholesterol at Weeks 52 and 78

Blood samples were drawn after a minimum 10-hour fast at pre-specified intervals. Percent change from Baseline was calculated as: Total cholesterol value at Week 52/Week 78 minus Parent Study Baseline value divided by Parent Study Baseline value multiplied by 100. Baseline was defined as the mean of the values at screening and predose Day 1/Week 0 (Visit T1) in the Parent Study.

Time frame:
Baseline; Week 52 and Week 78
Reported as:
Mean · percent change
Percent Change From Parent Study Baseline in Total Cholesterol at Weeks 52 and 78
percent changePlacebo; Bempedoic AcidBempedoic Acid; Bempedoic AcidOLE Bempedoic Acid
Week 52-9.01 ± 15.961-9.79 ± 16.893-9.53 ± 16.582
Week 78-10.15 ± 16.541-9.34 ± 18.030-9.61 ± 17.545
SecondaryPercent Change From Parent Study Baseline in Apolipoprotein B (ApoB) at Weeks 52 and 78

Blood samples were drawn after a minimum 10-hour fast at pre-specified intervals. Percent change from Baseline was calculated as: ApoB value at Week 52/Week 78 minus Parent Study Baseline value divided by Parent Study Baseline value multiplied by 100. Baseline was defined as the mean of the values at screening and predose Day 1/Week 0 (Visit T1) in the Parent Study.

Time frame:
Baseline; Week 52 and Week 78
Reported as:
Mean · percent change
Percent Change From Parent Study Baseline in Apolipoprotein B (ApoB) at Weeks 52 and 78
percent changePlacebo; Bempedoic AcidBempedoic Acid; Bempedoic AcidOLE Bempedoic Acid
Week 52-7.5 ± 20.52-8.8 ± 21.89-8.4 ± 21.44
Week 78-7.6 ± 22.15-7.0 ± 22.33-7.2 ± 22.26
SecondaryPercent Change From Parent Study Baseline in High-Sensitivity C-Reactive Protein (Hs-CRP) at Weeks 52 and 78

Blood samples were drawn after a minimum 10-hour fast at pre-specified intervals. Percent change from Baseline was calculated as: hs-CRP value at Week 52/Week 78 minus Parent Study Baseline value divided by Parent Study Baseline value multiplied by 100. Baseline was defined as the mean of the values at screening and predose Day 1/Week 0 (Visit T1) in the Parent Study.

Time frame:
Baseline; Week 52 and Week 78
Reported as:
Median · percent change
Percent Change From Parent Study Baseline in High-Sensitivity C-Reactive Protein (Hs-CRP) at Weeks 52 and 78
percent changePlacebo; Bempedoic AcidBempedoic Acid; Bempedoic AcidOLE Bempedoic Acid
Week 52-11.553 (-53.120 to 44.167)-19.709 (-52.617 to 34.151)-16.476 (-52.874 to 41.667)
Week 78-15.005 (-50.510 to 44.000)-18.065 (-51.701 to 50.505)-16.740 (-51.577 to 48.279)
SecondaryPercent Change From Parent Study Baseline in Triglycerides at Weeks 52 and 78

Blood samples were drawn after a minimum 10-hour fast at pre-specified intervals. Percent change from Baseline was calculated as: Triglycerides value at Week 52/Week 78 minus Parent Study Baseline value divided by Parent Study Baseline value multiplied by 100. Baseline was defined as the mean of the values at screening and predose Day 1/Week 0 (Visit T1) in the Parent Study.

Time frame:
Baseline; Week 52 and Week 78
Reported as:
Median · percent change
Percent Change From Parent Study Baseline in Triglycerides at Weeks 52 and 78
percent changePlacebo; Bempedoic AcidBempedoic Acid; Bempedoic AcidOLE Bempedoic Acid
Week 52-4.31 (-24.08 to 21.75)-3.21 (-22.76 to 23.50)-3.49 (-23.02 to 22.40)
Week 78-5.00 (-25.54 to 24.26)-2.60 (-21.41 to 27.47)-3.08 (-22.78 to 26.67)
SecondaryPercent Change From Parent Study Baseline in High-Density Lipoprotein Cholesterol (HDL-C) at Weeks 52 and 78

Blood samples were drawn after a minimum 10-hour fast at pre-specified intervals. Percent change from Baseline was calculated as: HDL-C value at Week 52/Week 78 minus Parent Study Baseline value divided by Parent Study Baseline value multiplied by 100. Baseline was defined as the mean of the values at screening and predose Day 1/Week 0 (Visit T1) in the Parent Study.

Time frame:
Baseline; Week 52 and Week 78
Reported as:
Mean · percent change
Percent Change From Parent Study Baseline in High-Density Lipoprotein Cholesterol (HDL-C) at Weeks 52 and 78
percent changePlacebo; Bempedoic AcidBempedoic Acid; Bempedoic AcidOLE Bempedoic Acid
Week 52-4.54 ± 16.747-7.06 ± 15.638-6.20 ± 16.060
Week 78-3.42 ± 17.555-4.91 ± 16.731-4.41 ± 17.018
SecondaryPercent Change From Open-Label Extension (OLE) Study Baseline in LDL-C at Weeks 52 and 78

Blood samples were drawn after a minimum 10-hour fast at pre-specified intervals. Percent change from Baseline was calculated as: LDL-C value at Week 52/Week 78 minus OLE Study Baseline value divided by Parent Study Baseline value multiplied by 100. Baseline was defined as the last non-missing record prior to treatment start in the OLE Study.

Time frame:
Baseline; Week 52 and Week 78
Reported as:
Mean · percent change
Percent Change From Open-Label Extension (OLE) Study Baseline in LDL-C at Weeks 52 and 78
percent changePlacebo; Bempedoic AcidBempedoic Acid; Bempedoic AcidOLE Bempedoic Acid
Week 52-12.4 ± 23.793.6 ± 27.49-1.8 ± 27.35
Week 78-14.3 ± 25.793.7 ± 30.63-2.3 ± 30.31
SecondaryMean Change From OLE Baseline in LDL-C at Weeks 52 and 78

Blood samples were drawn after a minimum 10-hour fast at pre-specified intervals. Mean change from Baseline was calculated as: Mean LDL-C value at Week 52/Week 78 minus Mean OLE Study Baseline value. Baseline was defined as the last non-missing record prior to treatment start in the OLE Study.

Time frame:
Baseline; Week 52 and Week 72
Reported as:
Mean · mg/dL
Mean Change From OLE Baseline in LDL-C at Weeks 52 and 78
mg/dLPlacebo; Bempedoic AcidBempedoic Acid; Bempedoic AcidOLE Bempedoic Acid
Week 52-14.7 ± 25.630.6 ± 24.92-4.6 ± 26.17
Week 78-17.0 ± 28.560.2 ± 26.04-5.5 ± 28.08
SecondaryPercent Change From OLE Baseline in Non-HDL-C at Weeks 52 and 78

Blood samples were drawn after a minimum 10-hour fast at pre-specified intervals. Percent change from Baseline was calculated as: non-HDL-C value at Week 52/Week 78 minus OLE Study Baseline value divided by OLE Study Baseline value multiplied by 100. Baseline was defined as the last non-missing record prior to treatment start in the OLE Study.

Time frame:
Baseline; Week 52 and Week 78
Reported as:
Mean · percent change
Percent Change From OLE Baseline in Non-HDL-C at Weeks 52 and 78
percent changePlacebo; Bempedoic AcidBempedoic Acid; Bempedoic AcidOLE Bempedoic Acid
Week 52-10.0 ± 20.812.9 ± 23.98-1.4 ± 23.75
Week 78-11.8 ± 23.083.1 ± 28.02-1.9 ± 27.38
SecondaryPercent Change From OLE Baseline in Total Cholesterol at Weeks 52 and 78

Blood samples were drawn after a minimum 10-hour fast at pre-specified intervals. Percent change from Baseline was calculated as: Total Cholesterol value at Week 52/Week 78 minus OLE Study Baseline value divided by OLE Study Baseline value multiplied by 100. Baseline was defined as the last non-missing record prior to treatment start in the OLE Study.

Time frame:
Baseline; Week 52 and Week 78
Reported as:
Mean · percent change
Percent Change From OLE Baseline in Total Cholesterol at Weeks 52 and 78
percent changePlacebo; Bempedoic AcidBempedoic Acid; Bempedoic AcidOLE Bempedoic Acid
Week 52-8.7 ± 15.781.3 ± 17.23-2.1 ± 17.40
Week 78-9.7 ± 17.392.1 ± 19.88-1.8 ± 19.88
SecondaryPercent Change From OLE Baseline ApoB at Weeks 52 and 78

Blood samples were drawn after a minimum 10-hour fast at pre-specified intervals. Percent change from Baseline was calculated as: ApoB value at Week 52/Week 78 minus OLE Study Baseline value divided by OLE Study Baseline value multiplied by 100. Baseline was defined as the last non-missing record prior to treatment start in the OLE Study.

Time frame:
Baseline; Week 52 and Week 78
Reported as:
Mean · percent change
Percent Change From OLE Baseline ApoB at Weeks 52 and 78
percent changePlacebo; Bempedoic AcidBempedoic Acid; Bempedoic AcidOLE Bempedoic Acid
Week 52-10.0 ± 19.940.2 ± 21.48-3.2 ± 21.51
Week 78-10.2 ± 21.842.4 ± 23.16-1.8 ± 23.49
SecondaryPercent Change From OLE Baseline in Hs-CRP at Weeks 52 and 78

Blood samples were drawn after a minimum 10-hour fast at pre-specified intervals. Percent change from Baseline was calculated as: hs-CRP value at Week 52/Week 78 minus OLE Study Baseline value divided by OLE Study Baseline value multiplied by 100. Baseline was defined as the last non-missing record prior to treatment start in the OLE Study.

Time frame:
Baseline; Week 52 and Week 78
Reported as:
Median · percent change
Percent Change From OLE Baseline in Hs-CRP at Weeks 52 and 78
percent changePlacebo; Bempedoic AcidBempedoic Acid; Bempedoic AcidOLE Bempedoic Acid
Week 52-11.720 (-50.315 to 38.433)-2.174 (-39.583 to 61.765)-4.856 (-43.750 to 52.800)
Week 78-14.953 (-50.549 to 43.333)3.774 (-36.842 to 69.136)-2.538 (-41.509 to 60.268)
SecondaryPercent Change From OLE Baseline in Triglycerides at Weeks 52 and 78

Blood samples were drawn after a minimum 10-hour fast at pre-specified intervals. Percent change from Baseline was calculated as: Triglycerides value at Week 52/Week 78 minus OLE Study Baseline value divided by OLE Study Baseline value multiplied by 100. Baseline was defined as the last non-missing record prior to treatment start in the OLE Study.

Time frame:
Baseline; Week 52 and Week 78
Reported as:
Median · percent change
Percent Change From OLE Baseline in Triglycerides at Weeks 52 and 78
percent changePlacebo; Bempedoic AcidBempedoic Acid; Bempedoic AcidOLE Bempedoic Acid
Week 520.3 (-22.4 to 23.6)0.9 (-20.2 to 25.2)0.7 (-20.7 to 24.3)
Week 78-2.0 (-23.8 to 24.1)2.2 (-19.2 to 27.2)0.9 (-20.9 to 26.6)
SecondaryPercent Change From OLE Baseline in HDL-C at Weeks 52 and 78

Blood samples were drawn after a minimum 10-hour fast at pre-specified intervals. Percent change from Baseline was calculated as: HDL-C value at Week 52/Week 78 minus OLE Study Baseline value divided by OLE Study Baseline value multiplied by 100. Baseline was defined as the last non-missing record prior to treatment start in the OLE Study.

Time frame:
Baseline; Week 52 and Week 78
Reported as:
Mean · percent change
Percent Change From OLE Baseline in HDL-C at Weeks 52 and 78
percent changePlacebo; Bempedoic AcidBempedoic Acid; Bempedoic AcidOLE Bempedoic Acid
Week 52-4.3 ± 18.36-0.6 ± 14.88-1.8 ± 16.23
Week 78-3.4 ± 17.772.7 ± 23.600.7 ± 22.01

Adverse events

Collected over Up to Week 82. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo; Bempedoic Acid3/492 (0.6%)97/492 (19.7%)108/492 (22%)
Bempedoic Acid; Bempedoic Acid10/970 (1%)202/970 (20.8%)201/970 (20.7%)
OLE Bempedoic Acid13/1,462 (0.9%)299/1,462 (20.5%)309/1,462 (21.1%)
Most frequent serious events
Showing 10 of 219
Most frequent serious events
EventPlacebo; Bempedoic AcidBempedoic Acid; Bempedoic AcidOLE Bempedoic Acid
Coronary artery diseaseCardiac disorders3/49215/97018/1462
Atrial fibrillationCardiac disorders2/49212/97014/1462
PneumoniaInfections and infestations6/4929/97015/1462
Angina unstableCardiac disorders3/49210/97013/1462
Angina pectorisCardiac disorders5/4929/97014/1462
Non-cardiac chest painGeneral disorders1/4928/9709/1462
OsteoarthritisMusculoskeletal and connective tissue disorders4/4926/97010/1462
Inguinal herniaGastrointestinal disorders4/4921/9705/1462
Peripheral ischaemiaVascular disorders4/4920/9704/1462
Acute myocardial infarctionCardiac disorders2/4927/9709/1462
Most frequent other events
Most frequent other events
EventPlacebo; Bempedoic AcidBempedoic Acid; Bempedoic AcidOLE Bempedoic Acid
NasopharyngitisInfections and infestations33/49286/970119/1462
Urinary tract infectionInfections and infestations40/49249/97089/1462
ArthralgiaMusculoskeletal and connective tissue disorders30/49238/97068/1462
Upper respiratory tract infectionInfections and infestations18/49249/97067/1462

Baseline characteristics

Baseline data are reported for members of the Safety Population, comprised of all enrolled participants who received at least 1 dose of bempedoic acid in the Open-Label Extension (OLE) Study.

Age, Continuous
Age, Continuous(years)Placebo; Bempedoic AcidBempedoic Acid; Bempedoic AcidTotal
Mean67.5 ± 8.5466.5 ± 8.8166.9 ± 8.73
Sex: Female, Male
Sex: Female, Male(Participants)Placebo; Bempedoic AcidBempedoic Acid; Bempedoic AcidTotal
Female142239381
Male3507311081
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Placebo; Bempedoic AcidBempedoic Acid; Bempedoic AcidTotal
American Indian or Alaska Native022
Asian5914
Native Hawaiian or Other Pacific Islander011
Black or African American62329
White4809311411
More than one race011
Unknown or Not Reported134
Low-density lipoprotein cholesterol (LDL-C): Parent Study
Low-density lipoprotein cholesterol (LDL-C): Parent Study(milligrams per deciliter (mg/dL))Placebo; Bempedoic AcidBempedoic Acid; Bempedoic AcidTotal
Mean98.96 ± 24.171102.94 ± 29.899101.60 ± 28.156
Non-high-density lipoprotein cholesterol (N-HDL-C): Parent Study
Non-high-density lipoprotein cholesterol (N-HDL-C): Parent Study(mg/dL)Placebo; Bempedoic AcidBempedoic Acid; Bempedoic AcidTotal
Mean126.41 ± 28.531130.09 ± 34.727128.85 ± 32.809
Total cholesterol: Parent Study
Total cholesterol: Parent Study(mg/dL)Placebo; Bempedoic AcidBempedoic Acid; Bempedoic AcidTotal
Mean175.33 ± 30.026178.94 ± 36.057177.73 ± 34.179
Apolipoprotein B: Parent Study
Apolipoprotein B: Parent Study(mg/dL)Placebo; Bempedoic AcidBempedoic Acid; Bempedoic AcidTotal
Mean85.1 ± 19.2588.2 ± 21.7187.2 ± 20.97
High-sensitivity C-reactive protein (hs-CRP): Parent Study
High-sensitivity C-reactive protein (hs-CRP): Parent Study(milligrams per Liter (mg/L))Placebo; Bempedoic AcidBempedoic Acid; Bempedoic AcidTotal
Median1.515 (0.810 to 3.490)1.500 (0.700 to 3.220)1.510 (0.750 to 3.320)

9 further baseline measures are reported on the registry.

08

Study locations

3 sites
  • Jedidiah Clinical Research
    Tampa, Florida 33607, United States
  • L-MARC Research Center
    Louisville, Kentucky 40213, United States
  • Sentral Clinical Research Services
    Cincinnati, Ohio 45236, United States
09

References and documents

Publications

  • Pinkosky SL, Newton RS, Day EA, Ford RJ, Lhotak S, Austin RC, Birch CM, Smith BK, Filippov S, Groot PHE, Steinberg GR, Lalwani ND. Liver-specific ATP-citrate lyase inhibition by bempedoic acid decreases LDL-C and attenuates atherosclerosis. Nat Commun. 2016 Nov 28;7:13457. doi: 10.1038/ncomms13457. PubMed 27892461 ↗
  • Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, Goldberg AC, Gordon D, Levy D, Lloyd-Jones DM, McBride P, Schwartz JS, Shero ST, Smith SC Jr, Watson K, Wilson PW, Eddleman KM, Jarrett NM, LaBresh K, Nevo L, Wnek J, Anderson JL, Halperin JL, Albert NM, Bozkurt B, Brindis RG, Curtis LH, DeMets D, Hochman JS, Kovacs RJ, Ohman EM, Pressler SJ, Sellke FW, Shen WK, Smith SC Jr, Tomaselli GF; American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014 Jun 24;129(25 Suppl 2):S1-45. doi: 10.1161/01.cir.0000437738.63853.7a. Epub 2013 Nov 12. No abstract available. Erratum In: Circulation. 2014 Jun 24;129(25 Suppl 2):S46-8. Circulation. 2015 Dec 22;132(25):e396. doi: 10.1161/CIR.0000000000000346. PubMed 24222016 ↗
  • Goldberg AC, Hopkins PN, Toth PP, Ballantyne CM, Rader DJ, Robinson JG, Daniels SR, Gidding SS, de Ferranti SD, Ito MK, McGowan MP, Moriarty PM, Cromwell WC, Ross JL, Ziajka PE; National Lipid Association Expert Panel on Familial Hypercholesterolemia. Familial hypercholesterolemia: screening, diagnosis and management of pediatric and adult patients: clinical guidance from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J Clin Lipidol. 2011 Jun;5(3 Suppl):S1-8. doi: 10.1016/j.jacl.2011.04.003. Epub 2011 Apr 12. PubMed 21600525 ↗
  • Pollex RL, Joy TR, Hegele RA. Emerging antidyslipidemic drugs. Expert Opin Emerg Drugs. 2008 Jun;13(2):363-81. doi: 10.1517/14728214.13.2.363. PubMed 18537526 ↗
  • Sharrett AR, Ballantyne CM, Coady SA, Heiss G, Sorlie PD, Catellier D, Patsch W; Atherosclerosis Risk in Communities Study Group. Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins A-I and B, and HDL density subfractions: The Atherosclerosis Risk in Communities (ARIC) Study. Circulation. 2001 Sep 4;104(10):1108-13. doi: 10.1161/hc3501.095214. PubMed 11535564 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2017 to primary completion in Nov 2019, 33 months.

Results were first posted in Dec 2020, 1 year 1 month after primary completion.

Of 122 industry-sponsored phase 3 interventional studies under Hypercholesterolemia, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's 33 months is above that.

Counting every sponsor, half of 125 studies reached it within 18 months; a quarter within 10 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 24, 2017
First posted
Mar 1, 2017
StartActual
Feb 3, 2017
Primary completionActual
Nov 5, 2019
CompletionActual
Nov 5, 2019
Results first posted
Dec 22, 2020
Last update
Mar 1, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 1, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03067441
Responsible party
Sponsor
First posted
Mar 1, 2017
Start date
Feb 3, 2017
Primary completion
Nov 5, 2019
Completion
Nov 5, 2019
Results posted
Dec 22, 2020
Last update
Mar 1, 2021

Study contacts

Medical Director
study director · Esperion Therapeutics, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bempedoic acid

Start the discussion